This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanaka, Y. Articles by Kobayashi, Y. Search for Related Content PubMed PubMed Citation Articles by Tanaka, Y. Articles by Kobayashi, Y.

Inhibition of HT-29 Human Colon Cancer Growth under the Renal Capsule of Severe Combined Immunodeficient Mice by an Analogue of 1,25-Dihydroxyvitamin D₃, DD-003¹

Department of Veterans Affairs Medical Center [Y. T., A. S. W] and Department of Medicine, Albany Medical College [Y. T.], Albany, New York 12208; Iwaki Meisei University, Iwaki, Fukushima 970 [N. I.]; MEC Laboratory, Daikin Industries, Tsukuba, Ibaraki 305 [K. I., Y. K]; and Department of Microbiology, Aichi Medical University, Nagakute, Aichi 480-11 [M. K.], Japan

An analogue of 1,25-dihydroxyvitamin D₃, 22(S)-24-homo-26,26,26,27,27,27-hexafluoro-1,22,25-trihydroxyvitamin D₃ (DD-003), showed 10-fold greater inhibiting effect than 1,25-dihydroxyvitamin D₃ on the growth of HT-29 human colonic adenocarcinoma cells in culture. To examine the anticancer activity of DD-003 in vivo, a fibrin clot of HT-29 cells was prepared with fibrinogen and thrombin and implanted under the renal capsule of the severe combined immunodeficient mouse. Starting 7 days after implantation of HT-29 tumor, mice were given 3 µg/kg body weight of DD-003 or the vehicle i.p. every other day for 5 times. The HT-29 tumor grew rapidly in control mice; malignant growth was clearly observed with mitosis, massive tumor angiogenesis, and invasion into normal kidney tissue. Tumors in DD-003 treated mice were smaller with less invasion compared to the control. Administration of DD-003 inhibited growth of HT-29 tumor by 63%. Serum calcium concentrations and body weights of the treated mice were similar to those of the control. DD-003 inhibited growth of HT-29 tumor in a dose-dependent manner over the range of 0.1–10 µg/kg body weight, with no increase of serum calcium concentration observed at any dose level. When DD-003 was withdrawn after 2 weeks of treatment, tumor growth resumed. Since chemosensitivity tested by the subrenal capsule assay correlates well with clinical response, DD-003 may be clinically applicable in procedures such as postsurgical chemotherapy of colon cancer.

¹ Supported in part by the Department of Veterans Affairs Medical Center, Research Service, and Albany Research Institute, Albany, NY.

² To whom requests for reprints should be addressed, at Veterans Affairs Medical Center (151), 113 Holland Avenue, Albany, NY 12208.

Received 5/ 2/94. Accepted 8/ 4/94.

This article has been cited by other articles:

				S. Sundaram, M. J. Beckman, A. Bajwa, J. Wei, K. M. Smith, G. H. Posner, and D. A. Gewirtz QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol. Cancer Ther., November 1, 2006; 5(11): 2806 - 2814. [Abstract] [Full Text] [PDF]

				R. Gniadecki, B. Gajkowska, and M. Hansen 1,25-Dihydroxyvitamin D3 Stimulates the Assembly of Adherens Junctions in Keratinocytes: Involvement of Protein Kinase C Endocrinology, June 1, 1997; 138(6): 2241 - 2248. [Abstract] [Full Text] [PDF]